Country/Region: The Netherlands
PE Guidelines

Guideline for the Conduct of Economic Evaluations in Health Care (Dutch Version February 2016)
PDF in Dutch

PDF in English

PE Guidelines Source:

National Health Care Institute (ZIN)
http://www.zorginstituutnederland.nl

Additional Information:

Costing Manual
PDF in Dutch

Manual on Quality of Life Measurements
PDF in Dutch

Uncertainty and Value of Information
PDF in English

Last Webpage Update: Monday, January 15, 2018

PE Guidelines Key Features:

Key Features:  
Title and year of the document
Guideline for the Conduct of Economic Evaluations in Health Care (Dutch Version February 2016)   
Affiliation of authors
National Health Care Institute 
Purpose of the document
Providing guidance for conduct of EE studies for reimbursement issues in order to improve their quality, credibility and comparability 
Standard reporting format included
Yes 
Disclosure
Yes 
Target audience of funding/ author's interests
Who conduct economic evaluations or evaluate the economic evaluations studies (decision makers) 
Perspective
Societal perspective. Report unrelated medical costs in life years gained seperately.  
Indication
Approved indication; although sometimes off-label use is considered for comparator  
Target population
Be clearly specify 
Subgroup analysis
Yes 
Choice of comparator
Standard of care or usual care in the Netherlands 
Time horizon
Life time 
Assumptions required
Yes 
Preferred analytical technique
CUA  
Costs to be included
Societal perspective. Report unrelated medical costs in life years seperately. 
Source of costs
Reference prices list should be used 
Modeling
Yes, requires details 
Systematic review of evidences
Yes, encourage meta-analysis 
Preference for effectiveness over efficacy
Yes, modelling on trial data and other sources is required  
Preferred outcome measure
QALY and optional other measures of effectiveness like life years gained (LYG)  
Preferred method to derive utility
EQ-5D-5L using Dutch value set  
Equity issues stated
Yes 
Discounting costs
4% 
Discounting outcomes
1.5% 
Sensitivity analysis-parameters and range
All key uncertain parameters, within a defined area and best/worst case scenario 
Sensitivity analysis-methods
One-way, multi-way or scenario and probabilistic analysis 
Presenting results
Must be clear. Total costs and effects, incremental costs and effects. Results sensitivity analysis in tables and appropriate figures 
Incremental analysis
Yes 
Total costs vs effectiveness (cost/effectiveness ratio)
Yes 
Portability of results (Generalizability)
Study must refer to national context; utilities preferable calculated using Dutch value sets  
Financial impact analysis
Yes 
Mandatory or recommended or voluntary
Mandatory 

Acknowledgement: Saskia Knies, PhD, Pharmacoeconomics Advisor, Zorginstituut Nederland (ZIN), Diemen, The Netherlands and Maarten J. IJzerman, PhD, Professor of Clinical Epidemiology & Health Technology Assessment (HTA) and Head, Department of Health Technology & Services Research, University of Twente, Enschede, The Netherlands

Country Selection Page | PE Guidelines Index Page